ICLE 2022 | Enhancing CAR T-cells with an AvidCAR platform

Michael Traxlmayr, PhD, University of Natural Resources and Life Sciences, Vienna, Austria, provides an overview of the development of an avidity-controlled CAR (AvidCAR) platform and its potential applications in regulating the specificity of chimeric antigen receptors (CAR) T-cell therapy. AvidCARs have a lower antigen binding affinity compared to typical CAR T-cells and the reduced affinity results in increased tumor specificity as AvidCARs are dependent on bivalent antigen integration for activation. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.